Childhood Trauma And Cannabis Interactions In Affecting Psychosis Onset: Role Of The Anterior-Posterior Axis Of The Hippocampus and Differences In Cannabis Use Before or After Psychosis Onset

Elisabetta C. del Re[*1,2] , Walid Yassine[1], Victor Zeng[1], Sarah Keedy[3], Ney Alliey-Rodriguez[3], Elena Ivleva[4], Scott Hill[5], Nicole Rychagov[1], Jennifer E. McDowell[6], Paulo Lizano[1], Elliot Gershon[3], Godfrey Pearlson[7], John A. Sweeney[3], Brett Clementz[6], Carol Tamminga[4], Matcheri Keshavan[1]

[1]Harvard Medical School, [2] VA Boston HealthCare System, [3]University of Chicago, [4]University of Texas Southwestern Medical Center, [5]Rosalind Franklin University, [6]University of Georgia, [7]Yale University, [8]University of Cincinnati, [9]University of Texas Rio Grande.

Corresponding Authors: Prof. Matcheri Keshavan, mkeshava@bidmc.harvard.edu
Dr. Elisabetta C. del Re, Elisabetta_delre@hms.harvard.edu

Number of Figures: 3
Number of Tables: 2
Supplementary Material

Key Points

Question: Are there interactive effect of cannabis use (CA) and childhood trauma (CHT) on the onset age of psychosis (AO) and symptomatology? Are these effects mediated by the hippocampus (HP)? Does the schizophrenia polygenic risk score (SZ-PGRS) influence how these factors impact AO?

Findings: In this multicenter study including 1288 participants with/out psychosis and with/out CA, high CHT or high CA were independently correlated with AO, these factors interacted to further lower AO. The HP was affected by CHT and mediated CHT effects on AO only in probands that used CA before AO. The PGRS was higher in probands, particularly in probands with CA use before AO.

Meaning: and CHT. In youth with less severe CHT and moderate levels of CA, CHT and CA may interact to predict speed psychosis onset. In the context of a “three hit” model, the SZ-PGRS in probands with CA before AO might represent a first hit that together with CHT (2nd) and CA (third hit) induces earlier onset of psychotic symptomatology. Reducing CA may be a promising strategy for preventing or delaying onset of psychosis, especially those at genetic risk and with a history of CA.

STRUCTURED ABSTRACT 350 WORDS

Importance: Cannabis (CA) and childhood trauma (CHT) independently increase the risk of earlier development of psychosis. The interaction between CA and CHT in relation to psychosis risk and its association with endocannabinoid receptor rich brain regions such as the hippocampus (HP), remains to be elucidated.

Objective: To determine whether CA use and CHT interact to increase risk of developing psychosis and/or lower age of psychosis onset (AO) through mediation by the HP changes and genetic risk, as measured by schizophrenia polygene scores (SZ-PGRS).

Design: This is a cross-sectional, case-control study.

Setting: Multicenter study in 5 metropolitan US regions.

Participants: 1288 participants, including 493 healthy controls (HC); 210 participants affected by bipolar disorder type 1 with psychosis; 281 by schizoaffective disorder; and 304 with schizophrenia diagnosed using the DSM IV-TR criteria. The HC subjects had no DSM Axis 1 disorder and no first-degree relative with psychotic illness.

Intervention(s) (for clinical trials) or Exposure(s) (for observational studies): CHT was assessed using the self-reported Childhood Trauma Questionnaire (CTQ); CA use, abuse, and dependence were assessed by self-reports and trained clinical interviewers. Neuroimaging, symptomatology, and cognition were also assessed.

Main Outcome(s) and Measure(s): The relation between age of psychosis onset i.e., time of first appearance of symptoms, measures of CHT, and CA use mediated by the HP, cognition and the SZ-PGRS.

Results: In survival analysis, low CTQ and CA acted synergistically to lower AO. At high CHT or abuse/dependence CA, CHT or CA were individually sufficient to affect AO. CHT relation with AO is mediated by the HP volume in CA users before AO. Higher SZ-PGRS in probands versus HC, was driven by probands with CA use before AO. Cognition was inversely related to CHT, and positively with higher AO.

Conclusions and Relevance: CA use and CHT interact to predict lower age of psychosis onset when moderate. Severe CHT is associated with lower age of psychosis onset irrespective of exposure to cannabis; while abuse/dependence levels of CA use are also sufficient to affect age at psychosis onset irrespective of CHT exposure. CHT effect on AO is mediated by the HP in probands with CA use before AO.

Age at psychosis onset (AO), associated symptomatology, and both brain morphology and function are modulated by the interaction of genetics and the environment (Beards et al., 2020; Cougnard et al., 2007; Pries et al., 2018). Cannabis (CA) use (Arsenault et al., 2004; Di Forti et al., 2009; 2014) and childhood trauma (CHT) individually increase the risk for emerging psychosis, with some evidence demonstrating an additive effects of CHT and CA in increasing the risk of psychopathology in adolescence (Harley et al., 2010). CHT encompasses different types of childhood adversities and is most often assessed with the self-reported Childhood Trauma Questionnaire (CTQ) (Bernstein & Fink, 1994). In animal models (Lo et al., 2021; Nemeroff, 2004; Lutz and Turecki, 2014) as well as in humans (Teicher, et al., 2012; 2018), CHT has been shown to affect the hippocampal (HP) volume, albeit not consistently (i.e., Aas et al., 2012). The hippocampus is also one of the brain regions richest in cannabinoid type 1 (CB1) receptors (Herkenham et al., 1990), the main central nervous system mediators of endogenous cannabinoids and exogenous CA (Egertova 2008; Herkenham 1990). In translational studies, the effects of CA on memory and learning have long been attributed to its effects on the HP (Drew and Miller, 1974; Miller and Branconnier, 1983; Essman, 1984; Hampson and Deadwyler, 1998).

CA use most often starts in adolescence (Kline et al 2022), a time of increasing risk-taking, part of the cognitive maturation process, as shown effectively in animal models (Hajos, 2008; Spear, 2004; Zlebnik and Cheer 2016) and also a crucial period for brain development (Peters et al., 2022), when the brain is particularly vulnerable to environmental insults, such as substance use (Power et al., 2021). The endocannabinoid system itself is refined during adolescence (Peters et al., 2022; Meier et al., 2020), which is also the period when first signs of psychosis and associated cognitive decline are most frequently observed (Keshavan et al., 2015).

The interaction of CHT and CA on the process of psychosis has been evaluated in relation to symptomatology and cognition (Carlisle et al 2021); but data on the age of onset of psychosis and mediation of CHT and CA by biological substrates and brain regions is llimited (Domen 2019; Peeters 2015). Studies on the accumulation of different genetic and environmental factors on risk of psychosis have indicated involvement of the basal

ganglia in the interaction (Samplin 2013; De Rosse 2014; Blair Thies 2020). Abnormalities of white matter derived fractional anisotropy in individuals affected by psychosis with high load of CHT and CA compared to controls and unaffected siblings has been shown (Domen 2019) as well as some evidence of a combined effect of childhood adversities and SZ polygenic risk, greater than the sum of each alone (Aas 2021).

In this study, we approach CA and CHT associations with HP and psychosis onset, by adopting a transdiagnostic method by employing the large and deeply phenotyped sample from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (BSNIP) 2 dataset that encompasses several mental disorders, including bipolar disorder type 1 (BP), schizoaffective disorder (SAD), and schizophrenia (SZ). The evidence of a common neurobiological substrate is robust (e.g., BSNIP studies: del Re 2021; Ivleva 2013; Sheffield 2017; and others, e.g.: Baker 2014, 2019; Anticevic 2014; Cole 2017) as well as the strong shared genomic relationships (Cross-Disorder Group of the Psychiatric Genomics Consortium, 2013; 2019). Our main hypotheses were that 1) CA use and CHT interact synergistically to lower AO; 2) the HP is a mediator of these interactive effects; and 3) the SZ-PGRS will be higher in probands with CA use before AO, compared to CA usage after AO. This latter hypothesis is based on the idea that in probands that develop PSY with preceeding CA, genetics might act as the first hit, CHT the second hit and CA the third hit. We analyzed the data according to presence or absence of psychosis and across a trans-diagnostic psychosis continuum for the purpose of disentangling CA versus non-CA as well as CHT versus non-CHT subjects in relation to AO. Other variables of interest were age of CA initiation; Cognition; symptomatology as well as the schizophrenia polygenic risk score for each participant. The HP was analyzed according to its anterior and posterior portions in addition to left and right whole volumes as in the previous study where we demonstrated differential abnormalities in psychoses according to the dorso-ventral division (del Re et al., 2021; see also McHugo et al., 2018). Further, elegant autoradiography binding studies of rat brains have shown denser binding of agonists in the dorsal hippocampus than in the ventral portion (Herkenham et al., 1991) where the rat dorsal HP corresponds to the human posterior HP.

Subjects

Participants were recruited from the multi-site B-SNIP 2 consortium, at Athens and Augusta, GA; Boston, MA; Chicago, IL; Dallas, TX; Hartford, CT. HCs were recruited alongside probands (PRO). All protocols described were approved by the respective local IRBs. Participants received a comprehensive symptom and cognition battery. PRO (N = 795) were assigned a DSM-IV-TR diagnostic classification based on interviews by trained clinical interviewers. HCs (N = 493) had no Axis I psychotic disorder nor had any first-degree family history of schizophrenia (SZ), schizoaffective disorder (SAD), or bipolar disorder. Participants with recent substance use disorders (dependence within the past 3 months or abuse within the past 1 month) were excluded. None were under acute cannabis effects at the time of entry into study, as verified by a urine drug screen. No PRO met the DSM-IV criteria for cannabis induced psychotic disorders. Participants were evaluated with the global assessment of function (GAF) and the composite score using the Brief Assessment of Cognition for Schizophrenia (BACS, Keefe et al., 2004). BACS scores were pre-adjusted for age and sex, z-transformed and then winsorized to +/- 4.0 standard deviations. Daily dose chlorpromazine equivalent (CPZ) were calculated for those taking antipsychotics. Childhood trauma data were acquired by supervised self-reported Childhood Trauma Questionnaire (CTQ) (Bernstein 1994). The age of psychotic symptoms onset (AO) as well as cannabis use data were acquired by trained clinicians using a semi-structured manner, as well as the SCID interviews. AO was determined as the first appearance of psychosis symptomatology. Cannabis use was categorized as ever use, yes or no; and amount of usage, recreational, defined as seldomly in the past; abuse and dependence according to the definition of the DSM IV (American Psychiatric Association 1994). We first determined the effect of CA on participants without distinction of CA usage timing with respect of psychosis onset. We then determined the effect of CA on psychosis onset when CA was initiated before or after psychosis symptomatology onset, with N=208 participants not using CA before AO; and N=550 using CA before AO.

Genotypes and Polygenic Risk Scores calculation

Genotypes were assessed from blood DNA at the Broad Institute using the Illumina Infinium® Global Screening Array-24 v1.0. (GSA) (Illumina Inc., San Diego, CA, USA),

containing 688,032 markers mapped to the human genome GRCh37/hg19 reference build. For details, please see Supplementary Material.

Polygenic Risk Scores (SZ-PGRS) were generated with PRSice (www.prsice.info) using the Psychiatric Genomic Consortium Schizophrenia 2 (PGC-SZ2) training dataset (1), following the Nature Protocol by Choi et al. 2020 (2). SZ-PGRS were generated for P thresholds 5e-8, 1e-6, 1e-4, 1e-3, 0.01, 0.05, 0.1, 0.2, 0.5 and 1. For group comparisons, the SZ-PGRS was corrected for the first five PCAs, age and sex.

Imaging

Participants received a 3 T MPRAGE scan based on Alzheimer's Disease Neuroimaging Initiative (ADNI) recommended protocol parameters [(Ivleva et al 2013)]. Each scan was quality checked for movement, ghosting, and other artifacts and processed with Freesurfer 7.1 (FS7.1). A computational atlas of the hippocampal formation that retrieves the volumetric hippocampal head (anterior) and body (posterior) measurements of each subfield was used (Iglesias et al., 2015). Each brain scan was rigorously assessed for quality by at least two independent raters. Brain scans with errors in hippocampal segmentation or in the overall cerebral cortex were not included in further analyses (<2%). Detailed delineation of the HP has been described in del Re et al., 2021. Estimated total intracranial volume (eTIV) was extracted from Freesurfer and used as a covariate in statistical analyses.

Statistical approach

Statistical analyses were performed using R (version 3.4.3) and SPSS v28. Demographic information between HC and PRO, were analyzed using univariate analyses (ANCOVA) and $\chi 2/F$ tests. Outliers were considered as >4 SD from the mean and winsorized. Additionally, demographic variable differences were assessed between controls and DSM groups. The left and right anterior and posterior hippocampal comparisons were performed using MANCOVA. For all analyses, data were corrected for age, sex, race, MRI acquisition sites, and in addition for the HP, the estimated total intracranial volume (eTIV). Correlations were also carried out with variables adjusted as mentioned above. For CTQ analyses, the CTQ total score was utilized. For Cox regression, the CTQ total

score was also operationalized in four strata or quartiles as: CTQ low score, 31-51; moderate, 51-71; moderate high, 71-91; high, 91-111 (McDonald et al., 2016; Begemann et al., 2021; Grillault Laroche et al., 2022). Where we found differences between males and females, we report those in the Results. Probability values were corrected for multiple comparisons using False Discovery Rate (FDR).

Participants

Our analysis included 493 HCs and 795 psychosis PRO (Table 1). Of the PRO, 304 were diagnosed with SZ, 210 with psychotic bipolar I disorder (BP), 281 with SAD. Significant differences were present in age, sex, and race. 550 participants had CA usage before AO; 208, after AO. The mean and SD of the composite BACS score and positive and negative symptoms between groups are summarized in Table I. A high percentage of PRO were treated with second-generation antipsychotics while less were on first generation antipsychotics. There were significant antipsychotic dose (CPZ equivalents) differences between SZ and BP and between SAD and BP (BP (348.55+-398.1, n=158) SAD (528,94+-1010.6, n=248) SZ (672.83+-1143.6, n=282). (Table 1; $p < 0.01$ for both comparisons). There were no significant correlations between CPZ equivalents and HP volumes, either in CA users or non-CA users. The SZ-PGRS was significantly higher in PRO compared to HC across all PGRS stringency values (Supplementary Figure 1A).

Anterior and Posterior Hippocampus

Our analysis confirms significantly smaller volumes of left and right anterior (aHP) and posterior (pHP) volumes between PRO as well as each diagnostic group and NC (Figure 1A).

Cannabis Use

All HC subjects were in the none or recreational type CA use, where we defined recreational as CA used seldomly in the past without meeting criteria for abuse or dependence. PRO were represented in all 4 categories: No CA use, recreational use, *abuse,* and *dependence*.

AO was significantly lower for CA users compared to that of non-CA users (F=4.24, p_{FDR} =0.039); with no significant difference in AO for CA users after or before AO (F=2.17, p_{FDR}= 0.091). The self-reported age of first CA use differed significantly in PRO across usage category (F=5.3; *p*<0.001) and was lower in PRO with CA usage before AO (F=40.3, p_{FDR}= 3.3946E-10). Overall, for PRO with CA dependence, age of first use was significantly lower than PRO with recreational CA type of use (*p*=0.009). The age of first CA use was significantly and positively correlated with the left and right HP in PRO, i.e., higher HP volume correlated with higher age at first use (left HP, r=0.11, *p*<0.001 and right HP, r=0.11, *p*<0.001). The total CTQ score differed significantly between CA users and non-users among PRO, with higher score in CA-using PRO (F =4.56; p=0.033). In PRO, the age of first CA use was significantly and inversely correlated with total CTQ score (r=-0.15, *p*=0.0003); thus, higher trauma correlated with younger age of CA use. The relationship between CHT and age at CA usage was driven by the group of participants with CA usage before AO (r=-0.23; p= 3.4041E-10), while for participants with CA usage after AO the relationship between CHT and age of CA was not significant (r=-0.06; p=0.373) as expected. The SZ-PGRS higher score in PRO vs HC, was driven by CA usage before AO (Supplementary Figure 1B).

Childhood Trauma

PRO had higher CTQ scores than HC, as expected. The total CHT score in PRO with CA usage before AO was significantly and negatively correlated with the right aHP (r=-0.11; p_{FDR}0.011) and the left and right pHP (r=-0.14; p_{FDR}=0.0004; and r=-0.12; p_{FDR}=0.003, respectively; Figure 1D), where to a higher CTQ score corresponded a lower HP volume. This correlation was absent in PRO with CA usage after AO (Figure 1C) and in HC (1B). In PRO with CA usage before AO, the total CTQ score was also significantly and negatively correlated with AO (r=-0.221; p=1.5581E-12). CHT was higher in PRO that started CA usage after AO (67.1$\pm$ 19.5 vs 59.0 $\pm$ 16.5, respectively; F=34.8, p= 5.4207E-9).

Symptomatology

Results of Symptomatology Correlations with Variables of interest are reported in the Supplementary Material.

Relationships between trauma, cannabis use, cognition, and the HP

The left and right aHP and pHP were positively and significantly correlated with BACS score in the whole PRO sample (r=0.20, p=2.9674E-7; r=0.194, p=6.2953E-7; r= 0.18, p=0.000004; r=0.17, p=0.000013) and in PRO with CA usage before AO (r=0.24, p=0.000004; r=0.24, p=0.000003; r=0.17, p=0.000886; r=0.15, p=0.004, respectively), but not in CA users after AO (all p>0.05). To determine whether there was a possible contribution of CTQ score in the correlation between cognition and hippocampus, we repeated the correlation analysis between HP and cognition, by co-varying for the total CTQ score. The results of the correlation with and without covarying for CTQ were similar and unaffected in the whole sample and in users of CA after AO while in CA users before AO, the significant relationship was lost, indicating that in PRO with CA usage before AO the relationship between BACS and HP in mediated by level of trauma.

Regression Analysis

In logistic regression, we included the following variables: the left and right anterior and posterior HP, the total CTQ, the composite BACS score, and the use or no use of CA. As control regions, we included the left and right lateral occipital volume. Of those variables, the left posterior HP (but not the control, i.e., occipital volumes), the composite BACS score, the CHT total and the ever use of CA, significantly predicted PRO vs HC status (Table II).

COX Regression analyses

In order to have a prediction model that takes into account the time to survival variable, we adopted a COX regression modeling and included the variables that are significantly predictive of group, PRO vs HC in logistic regression: CHT total; left pHP; BACS composite score; cannabis ever use. In this model, we also added an interaction term between cannabis ever use *CHT Total, to determine the predictive value of CA and CHT interaction on survival. Here, the dependent variable, survival, is time from birth to first

symptomatology. The data and results are shown in Supplementary Table I. The variables are all individually predictive including the interaction term CA*CHT. The negative B value for the interaction term CA*CHT, indicates CHT as more important than CA in lowering age of symptomatology onset.

Interactive effect of Trauma and CA use on age at first symptom onset: Odd Ratios

To determine the effect on AO of both CHT and CA use, according to different levels of CHT and CA, Kaplan-Meyer Survival analysis was employed. For this analysis, we considered the whole cohort of subjects, 1288 individuals, stratified by CHT trauma: low, moderate, medium, and high; and CA use: none, recreational, abuse and dependence. The dependent time variable was time of first reported symptom. As HC are not psychotic, their data in the analyses were censored. Results are shown in Figure 2A, B, C. As shown higher CTQ is associated with lower age at first psychosis symptoms in both individuals that do and do not use CA. For individuals that do use CA, recreational CA use in the presence of low trauma, is sufficient to affect time to survival, thus indicating an interactive relationship between trauma and cannabis use on psychosis onset date. Nonetheless, this does not apply at high CA and CHT. Replication of the analysis in CA users only before AO produces very similar results (Figure 2B). In Figure 2C, we tabulate COX regression analysis results for CHT* CA interactions at different levels of CA and different levels of CHT as in the Kaplan-Meyer analysis. The odd ratios are the Exp(B). Odd ratios are significant for CHT and CA individually; and significant for CHT*CA interaction at low CHT and CA, with increase in risk of earlier onset of symptomatology.

Log-rank (Mantel-Cox) testing: The overall comparison of different CA usage across different CHT strata indicate that survival curves are significantly different for various CA usage [Chi-Square: 247.9; 3 df (degree of freedom); $p_{FDR}<0.001$]. In Supplementary Table IV A and B, results of pairwise comparisons for survival at different levels of CHT and CA are reported. For the overall sample (Table IV A), as well as in CA users before AO (Table IV B), CA has an interactive effect with CHT when both CHT and CA are low or moderate. However, when CHT is high, use of any level of CA does not add to the risk of lower AO (Table IV).

Hippocampus Mediation of CHT relationships with AO

To understand the inter-relationship between CHT and HP, we carried out correlations while controlling for left and right aHP/pHP volumes. We hypothesized that if we controlled for the HP and the significant correlations between the variables disappears, this would indicate that the HP is an essential mediator in the relationships between these variables. We looked at this interaction in the whole sample and in users of CA before and after AO (Figure 3A and B). The significant CHT-AO correlation in the whole PRO sample is shown in Figure 3A. In Figure 3B , AO and CHT residuals after controlling for the HP are graphed in CA users before AO (top) and CA users after AO. As shown, in PRO with CA usage after AO, r values reveal medium-high effect sizes, indicating that the relationship between AO and CHT is not affected by controlling for the HP; For CA users before AO, controlling the HP renders AO-CHT correlation insignificant at recreational and abuse CA usage levels. When CA usage before AO is high, i.e., dependence, the HP has a lesser important role in mediating CHT and AO interaction than at lower CA usage, with significant correlation of residuals. Note that for some CA usage subgroups the sample is small, indicating these results as needing replication in a bigger sample.

Discussion

By employing a large, deeply phenotyped transdiagnostic dataset of psychosis probands and non psychotic controls, we tested the hypothesis of an interactive effect between CHT and CA on age of psychotic symptomatology onset and a possible mediation by the hippocampus. The analysis included: the relationships between age of symptomatology onset; CA use and age at first CA use; CHT total; Composite cognition score; left/right/anterior/posterior HP and the schizophrenia polygenic risk score.

In logistic regression, the left posterior HP, CHT, CA use and cognition all predict PRO vs no-PRO status. The variables are further correlated with age of symptomatology onset, where 1. lower cognition, 2. use of cannabis, and 3. higher CHT, predict younger age of psychosis onset. By use of COX regression analysis, in order to determine predictive value of those significant variables in relation to the dependent time variable i.e., the time

to onset of symptomatology, we showed that AO is lower with use of CA, lower BACS score, smaller volume of the left posterior HP, and lower with higher CHT. When introducing an interaction term, CA*CHT, CHT appears to have a stronger weight in lowering age of onset than CA. To determine the effect of different levels of CHT and CA on survival, we employed Kaplan-Meyer Survival analysis. Here interaction between the variables is apparent at intermediate levels of CHT and CA; instead, high levels of CHT or otherwise high levels of CA usage are individually sufficient to affect psychosis symptomatology onset. Odd ratios for the risk of individual variables on age of onset are included in Figure 2C. These are comparable to those reported by Di Forti (et al., 2019) for risk attributable to CA, albeit a little higher, and to those reported in the review by Shafer and Fisher (2011) with respect to CHT. Here we show that when combined, there is an additional risk over that of each variable alone especially at low levels of CHT and CA.

Overall, the results indicate that the left posterior HP, CA, CHT, and cognition all contribute to 1. Distinguishing PRO vs HC; and 2. Predicting lower age of symptomatology onset. In addition, at intermediate levels, CA and CHT interact to be associated with lower AO with odd ratios that are 1.2 to 0.8 times those of the individual variables. We report and confirm that the HP, a brain region rich in endocannabinoid receptors, and central to cognition, is affected by CHT (see Teicher et al., 2012), affected by CA (see Yucel et al., 2016) and impacted in psychosis (del Re et al., 2021). We confirm as well higher CHT in probands with psychosis (Church et al, 2017; Shevlin et al., 2007; Trotta et al., 2016).

By looking at PRO with CA usage before versus after AO, our data indicate some important differences in the two groups: 1. The HP is important in mediating the effect of CHT on AO, only in PRO with CA usage before AO. 2. CHT is higher in PRO with CA usage after AO. 3. When exploring the polygenic risk score, we confirm higher SZ-PGRS score in PRO compared to controls; with this difference driven by PRO using CA before AO. These novel results are best interpreted in the context of a three hits model, where polygenic risk score is the first hit, CHT the second and CA usage the third hit. We hypothesize that high CHT in PRO without CA usage before AO, might indicate that at a

certain threshold CHT might be independently sufficient to affect AO, without the necessity of other hits, such as CA. A similar model had been proposed in Keshavan 1999. A recent study of first episode psychosis shows some evidence of synergy between CHT and PGRS in affecting AO in schizophrenia (Aas et al., 2021). Nonetheless, comparison is limited as that study did not explore CA usage.

Our research contributes to the existing literature by highlighting that as CHT reaches high levels, those overshadow the effect of CA and significantly affect AO. At the same time, at high levels of CA, CHT becomes unnecessary in lowering AO. Overall, there is a threshold for the interactions of environmental factors and a dose response curve for the onset of psychosis symptomatology in response to different levels of CHT and CA as clearly indicated by the Kaplan-Meyer analysis shown in Figure 2, the comparison of survival curves and the odd ratios calculations for the different CA*CHT interactions.

CA is one of the substances most widely used in the world (UN Report 2020). Recently, the American Psychiatric Association (APA Official Action, December 2020) released recommendations that CA should be strictly regulated, including limitations in marketing to children and adolescents. Strong evidence indicates that CA use is associated with the risk of developing several types of mental illnesses, including psychotic disorders (Harley 2010; Arseneault 2004; Murray 2017) and psychotic experiences in the population at large (McGrath 2015; Legge 2019; Gage 2016; Large 2011; Kline 2022). There is overwhelming evidence as well that CHT is a risk factor for mental disorders (see review by Teicher 2012; also see WFSBP consensus paper, 2022), including depression (Anda 2002), borderline personality disorder (Zanarini 2000), post-traumatic stress disorder (Bremner 1995), and schizophrenia/ psychosis (Read 2005). CHT further increases the risk of substance use (Kendler 2000; Green 2010; Morgan 2016; McGrath 2017; De la Peña-Arteaga et al., 2021; Martinez-Mota et al., 2020; Li et al., 2016; Croft et al., 2019).

Cognition is impaired in many mental illnesses (Mesholam-Gately et al.,2009; Seidman et al., 2006; Thermenos et al., 2013) and literature indicates that it is affected by both trauma and CA usage. The interaction of environmental factors on cognition and psychosis remains a complex question, and while the interaction is evidently mediated by the brain, more research for explicit implications in psychosis is needed (for examples, see Teicher et al., 2016; Mondelli and Dazzan, 2019). Here, we show that cognition is

lower with CHT and CA and is predictive of lower age of symptomatology onset, although a smaller study has shown better cognition in SZ after adolescent CA use (Hanna et al., 2016).

There are limitations to our study. The cross-sectional nature of the study is a limitation, and will limit causal inferences. CA here is considered without knowledge of its composition, as 'miscellaneous CA'. Another limitation of the study is that the age at first symptomatology and CHT trauma are self reported as in the majority of studies in the literature. Nonetheless, the recent study by Danese (et al., 2021) indicates that the subjective experience of childhood maltreatment in psychopathology is meaningful compared to objective, clinical measures. Further, childhood trauma questionnaire (CTQ) correlations have been found to show reasonable correlations with prospective violence assessment in children and adolescents (Liebschutz et al., 2018). In subdividing groups of PRO in CA users before or after AO; and with different levels of CHT and CA, groups might be small in order to consider results final, with a need to replicate in a bigger sample.

Understanding the biological basis of environmental factors on psychosis, with a focus on adolescent populations, represents a first step toward prevention and treatment. Here, we show that treating CHT might prevent CA usage with consequences on psychosis risk. We show as well that high enough CHT or high CA usage are individually sufficient to affect AO. Results importantly indicate the necessity of focusing therapeutic interventions not only on extreme cases of CHT and CA, but in adolescent groups were CHT and CA are at intermediate levels and where CA*CHT synergy is active. We plan to replicate our results in a larger sample to confirm differences in PRO with CA usage before or after AO.

Acknowledgements

We thank all the participants that generously participated in the study. We also thank Dr. Giovanni Merola (Xi'an Jiaotong-Liverpool University,Suzhou, China) and Dr. Roger Davis, for statistical consulting. Dr. Davis was supported by the Harvard Catalyst.

The Harvard Clinical and Translational Science Center (National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health Award UL1 TR002541 and financial contributions from Harvard University and its affiliated academic health care centers. The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard Catalyst, Harvard University and its affiliated academic health care centers, or the National Institutes of Health.

Grant Support

The work was supported by MH077945 Dr. Pearlson; MH096942 to Dr. Keshavan; MH096913 to Dr. Tamminga; MH077862 to Dr. Sweeney; MH103368 to Dr. Gershon; MH096900 to Dr. Clementz; and by MH122759 to Dr. del Re.

Figures and Tables



Figure 1A, B, C, D. A. Volumetric differences of hippocampal volumes between probands (PRO) and controls (HC). **B.** Correlation between LpHP and total CHT is not significant in HC; **C.** Correlation between LpHP and Total CHT is not significant in PRO with CA usage after AO; **D.** Significant correlation between LpHP and total CHT in PRO with CA usage before AO. LaHP, left anterior hippocampus; RaHP, right anterior hippocampus; LpHP, left posterior hippocampus; RpHP, right posterior hippocampus. The whiskers in **A.** represent standard deviations. CHT, Childhood trauma; CA, cannabis.



C. Odd Ratios for Survival (Age at Symptomatology) for CA, CHT and CA * CHT By Strata

	B	SE	Wald	df	Sig.	Exp(B)	95.0% CI for Exp(B)		B Interaction terms CA *CHT	Exp(B) Interaction
							Lower	Upper		
CA Usage			218.99	3	<.001					
Recreational	1.360	0.123	121.99	1	<.001	3.898	3.062	4.962		
Abuse	1.937	0.197	97.10	1	<.001	6.936	4.719	10.196		
Dependence	2.050	0.155	174.51	1	<.001	7.767	5.73	10.527		
CHT strata			146.72	3	<.001					
CHT moderate	1.132	0.154	54.23	1	<.001	3.1	2.294	4.19		
CHT medium	1.826	0.203	80.88	1	<.001	6.208	4.17	9.241		
CHT High	2.135	0.231	85.16	1	<.001	8.458	5.374	13.311		
CA * CHT			53.87	9	<.001					
CA Recreational*CHT moderate	-0.509	0.183	7.72	1	0.005	0.601	0.42	0.861	0.851	2.34198767
CA Abuse*CHT moderate	-0.963	0.286	11.35	1	<.001	0.382	0.218	0.668	0.938	2.55486657
CA Dependence*CHT moderate	-0.999	0.224	19.84	1	<.001	0.368	0.237	0.571	1.051	2.8605102
CA Recreational*CHT medium	-0.891	0.236	14.21	1	<.001	0.41	0.258	0.652	0.469	1.598395
CA Abuse*CHT medium	-1.291	0.343	14.19	1	<.001	0.275	0.141	0.538	0.646	1.90789397
CA Dependence*CHT medium	-1.341	0.297	20.32	1	<.001	0.262	0.146	0.469	0.709	2.03195828
CA Recreational*CHT High	-1.264	0.277	20.84	1	<.001	0.283	0.164	0.486	0.096	1.10075906
CA Abuse *CHT High	-1.449	0.455	10.13	1	0.001	0.235	0.096	0.573	0.488	1.62905485
CA Dependence *CHT High	-1.854	0.356	27.13	1	<.001	0.157	0.078	0.315	0.196	1.21652691

Figure 2A, B and C. Time to Symptomatology Onset According to Different CA Usage and Timing and Levels of CHT. A. CA usage at any time during the lifetime at different levels of CHT and CA usage as indicated**. B**. Here, CA usage is considered only if before AO. CHT, Childhood trauma; CA, Cannabis; Cum, Cumulative; AO, Age at first Symptomatology. **C. COX Regression Analysis for CHT and CA and interaction terms CHT * CA at Different Strata.** CA and CHT individually increase risk of lower age of symptomatology onset. Odd ratios are the Exp (B). The Exp(B) for the interaction terms refer to the additional risk provided by the presence of both CA and CHT at different levels. The reference is CA usage. CHT * CA synergistically increase risk at recreational and moderate CHT [Exp(B)]. At high CA usage and CHT, the increase in risk denoted by the interaction becomes less important.



Figure 3 A and B. Relationship between Symptomatology Onset According to Different CA Usage, CHT and the Hippocampus. A. Correlation between AO and CHT according to different CA usage categories as indicated in the whole sample irrespective of CA onset timing. The r values in the graphs indicate medium-small effect sizes across usage type**. B**. Correlation of residuals between AO and CHT after controlling for the HP. **B** top: Correlations between AO and CHT in PRO with CA usage before AO at different levels of CA usage. **B bottom**: Correlations between AO and CHT in PRO with CA usage after AO at different levels of CA usage. In PRO with CA usage after AO, r values reveal medium-high effect sizes, indicating that the relationship between AO and CHT is not affected by controlling for the HP; For CA users before AO, control of the HP renders AO-CHT correlation insignificant at recreational and abuse CA usage levels. When CA usage before AO is high, i.e., dependence, the HP has a lesser mediating role than at lower CA usage, with significant correlation of residuals. AO, age of symptomatology onset; CHT, Childhood trauma; CA, Cannabis.

Tables

Table I. Clinical and Demographic Characteristics

	HC (n=493)	BP (n=210)	SAD (n=281)	SZ (n=304)	χ2/F	p value	Significant group comp.
Age (mean, SD)	34.30 (11.98)	36.11 (11.38)	39.81 (11.72)	38.12 (11.91)	15	<.001	SAD-HC***, SZ-HC***, SAD-BP***
Sex (M/F)	208/285	90/120	132/149	185/119	29	<.001	SZ-HC***, SZ-BP***, SZ-SAD**
Race (CU/AA/OTH)	253/157/83	146/40/24	114/112/55	106/151/47	77	<.001	BP-HC***, SAD-HC*, SZ-HC***, SAD-BP***, SZ-BP***
CA ever use (No/Yes)	218/275	36/174	63/218	78/226	73	<.001	BP-HC***, SAD-HC***, SZ-HC***, SZ-BP*
Total Childhood Trauma (mean, SD)	44.84 (10.09)	57.08 (17.74)	64.19 (19.37)	57.72 (16.85)	107	<.001	BP-HC***, SAD-HC***, SZ-HC***, SAD-BP***, SZ-SAD***
BACS Composite Score (mean, SD)	-0.38 (1.23)	-1.01 (1.29)	-1.58 (1.35)	-1.88 (1.31)	96	<.001	BP-HC***, SAD-HC***, SZ-HC***, SAD-BP***, SZ-BP***, SZ-SAD**
PANSS Total	--	54.38 (1.3)	63.97 (1.1)	62.87 (1.1)	16.9	<.001	SAD-BP***, SZ-BP***
PANSS Positive	--	12.78 (.42)	17.09 (.36)	16.59 (.35)	33.82	<.001	SAD-BP***, SZ-BP***
PANSS Negative	--	28.8 (.43)	31.88 (.37)	30.29 (.37)	15.8	<.001	SAD-BP***, SZ-BP***

PANSS General	**--**	**28.84 (.65)**	**31.88 (.56)**	**30.29 (.55)**	**6.1**	<.01	**SAD-BP****
LaHP (mean, SD)	**1588.96 (196.31)**	**1573.70 (225.7)**	**1525.72 (205.98)**	**1523.38 (200.68)**	**9.4**	<.001	**SAD-HC***, SZ-HC***, SAD-BP*, SZ-BP****
RaHP (mean, SD)	**1640.87 (194.92)**	**1637.30 (237.07)**	**1574.66 (203.42)**	**1575.44 (203.96)**	**11**	<.001	**SAD-HC***, SZ-HC***, SAD-BP**, SZ-BP****
LpHP (mean, SD)	**1733.08 (191.34)**	**1694.96 (194.80)**	**1665.82 (195.07)**	**1671.75 (187.17)**	**10**	<.001	**BP-HC*, SAD-HC***, SZ-HC*****
RpHP (mean, SD)	**1734.45 (180.67)**	**1720.80 (203.74)**	**1688.79 (203.90)**	**1688.76 (191.46)**	**5.2**	<.001	**SAD-HC**, SZ-HC*****

HC, healthy controls; SAD, schizoaffective; SZ, schizophrenia; BP, bipolar; L, left; R, right; aHP, anterior hippocampus; pHP, posterior hippocampus; BACS, Battery for the Assessment of cognition; CA, cannabis; CHT, trauma; PANNS, Positive and negative symptoms scale; CU, Caucasian; AA, African-American; OTH, Others; SD, standard deviation; *, $p<0.05$; **, $p<0.01$; ***, $p<0.001$

Table II. Regression analysis

Regression Analysis: Dependent Variable Proband versus Control Status

		B	S.E.	Wald	df	Sig.	Exp(B)
Step 1[a]	Left_hippocampus_anterior	.000	.001	.033	1	.855	1.000
	Right_hippocampus_anterior	.001	.001	1.000	1	.317	1.001
	Left_hippocampus_posterior	.002	.001	4.967	1	.026	1.002
	Right_hippocampus_posterior	-.001	.001	.709	1	.400	.999
	BACS	.643	.076	71.386	1	<.001	1.902
	CTQ	-.069	.008	69.171	1	<.001	.933
	Ever Use of CA, yes/no	-1.062	.187	32.323	1	<.001	.346
	Left_Lateraloccipital_volume	.000	.000	.050	1	.824	1.000
	Right_Lateraloccipital_volume	.000	.000	.411	1	.521	1.000
	Constant	-.002	1.118	.000	1	.999	.998

a. BACS, Battery for the assessment of cognition; CTQ, Childhood trauma; B, B values, S.E., Standard error; df, Degrees of Freedom; Sig., Significance; Exp, Exponent.

Supplementary Material

Supplementary Table I: Cox Regression analysis without Strata

	B	SE	Wald	df	Sig.	Exp(B)	95.0% CI for Exp(B) Lower	Upper
Left pHP	.000	.000	3.985	1	.046	1.000	.999	1.000
BACS composite	-.241	.030	63.812	1	<.001	.786	.740	.833
CA+/CA-	1.154	.270	18.326	1	<.001	3.170	1.869	5.377
CHT Total	.032	.004	68.513	1	<.001	1.032	1.025	1.040
CA+/CA-* CHT Total	-.012	.004	7.530	1	.006	.988	.979	.997

pHP, posterior hippocampus; BACS, Battery for the Assessment of cognition; CA, cannabis; CHT, trauma



B.

Univariate Tests: Comparison with HC SZ-PGRS Score										
Dependent Variable	CA Before/After (0=after; 1=be		Sum of Squa	df	Mean Square	F	Sig.	Partial Eta Squared	Noncent. Par	Observed Power
Pt_5e.08	0	Contrast	8.86E-07	1	8.86E-07	0.11	0.74	0	0.11	0.063
		Error	0.006	706	8.02E-06					
	1	Contrast	8.26E-05	1	8.26E-05	10.297	0.001	0.014	10.297	0.893
		Error	0.006	706	8.02E-06					
Pt_1e.06	0	Contrast	5.06E-06	1	5.06E-06	1.75	0.186	0.002	1.75	0.262
		Error	0.002	706	2.89E-06					
	1	Contrast	3.38E-05	1	3.38E-05	11.687	<.001	0.016	11.687	0.927
		Error	0.002	706	2.89E-06					
Pt_0.0001	0	Contrast	4.31E-07	1	4.31E-07	1.144	0.285	0.002	1.144	0.187
		Error	0	706	3.77E-07					
	1	Contrast	5.42E-06	1	5.42E-06	14.388	<.001	0.02	14.388	0.966
		Error	0	706	3.77E-07					
Pt_0.001	0	Contrast	5.36E-08	1	5.36E-08	0.484	0.487	0.001	0.484	0.107
		Error	7.80E-05	706	1.11E-07					
	1	Contrast	2.42E-06	1	2.42E-06	21.899	<.001	0.03	21.899	0.997
		Error	7.80E-05	706	1.11E-07					
Pt_0.01	0	Contrast	1.24E-08	1	1.24E-08	0.459	0.499	0.001	0.459	0.104
		Error	1.90E-05	706	2.70E-08					
	1	Contrast	4.32E-07	1	4.32E-07	16.007	<.001	0.022	16.007	0.979
		Error	1.90E-05	706	2.70E-08					
Pt_0.05	0	Contrast	8.69E-10	1	8.69E-10	0.098	0.754	0	0.098	0.061
		Error	6.26E-06	706	8.86E-09					
	1	Contrast	1.43E-07	1	1.43E-07	16.125	<.001	0.022	16.125	0.98
		Error	6.26E-06	706	8.86E-09					
Pt_0.1	0	Contrast	7.92E-14	1	7.92E-14	0	0.997	0	0	0.05
		Error	3.67E-06	706	5.20E-09					
	1	Contrast	7.41E-08	1	7.41E-08	14.244	<.001	0.02	14.244	0.965
		Error	3.67E-06	706	5.20E-09					
Pt_0.2	0	Contrast	1.58E-10	1	1.58E-10	0.053	0.818	0	0.053	0.056
		Error	2.11E-06	706	2.98E-09					
	1	Contrast	5.19E-08	1	5.19E-08	17.406	<.001	0.024	17.406	0.986
		Error	2.11E-06	706	2.98E-09					
Pt_0.5	0	Contrast	4.07E-10	1	4.07E-10	0.277	0.599	0	0.277	0.082
		Error	1.04E-06	706	1.47E-09					
	1	Contrast	2.32E-08	1	2.32E-08	15.763	<.001	0.022	15.763	0.978
		Error	1.04E-06	706	1.47E-09					
Pt_1	0	Contrast	4.24E-10	1	4.24E-10	0.433	0.511	0.001	0.433	0.101
		Error	6.91E-07	706	9.79E-10					
	1	Contrast	1.48E-08	1	1.48E-08	15.096	<.001	0.021	15.096	0.973
		Error	6.91E-07	706	9.79E-10					

Supplementary Figure 1A and **B. A.** SZ-PGRS is higher in PRO compared to HC at all levels of risk SZ variants included. SZ-PGRS was corrected for sex, age, ancestry. In blue, PRO, in purple, HC. The η^2 represent the effect size and the amount of variance the PGRS contributes to group differences in the BSNIP2 dataset. **B.** The SZ-PGRS higher score in PRO is driven by users of CA before onset.

Supplementary Figure 2A and B. Log Rank (Mantel-Cox): Pairwise Comparisons of Survival Across CHT and CA Levels curves (A) In the whole sample; (B) In CA users before AO.

A

Pairwise Comparisons

			none		recreational		abuse		dependence	
	CHT Strata	CA Usage	Chi-Square	Sig.	Chi-Square	Sig.	Chi-Square	Sig.	Chi-Square	Sig.
Log Rank (Mantel-Cox)	low	none			132.844	**<.001**	143.414	**<.001**	229.411	**<.001**
		recreational	132.844	**<.001**			11.829	**<.001**	23.181	**<.001**
		abuse	143.414	**<.001**	11.829	**<.001**			.252	.615
		dependence	229.411	**<.001**	23.181	**<.001**	.252	.615		
	moderate	none			45.025	**<.001**	20.156	**<.001**	44.638	**<.001**
		recreational	45.025	**<.001**			.018	.893	1.305	.253
		abuse	20.156	**<.001**	.018	.893			.202	.653
		dependence	44.638	**<.001**	1.305	.253	.202	.653		
	medium	none			5.154	**.023**	3.892	**.049**	5.273	**.022**
		recreational	5.154	**.023**			.089	.766	.517	.472
		abuse	3.892	**.049**	.089	.766			.004	.951
		dependence	5.273	**.022**	.517	.472	.004	.951		
	high	none			**.021**	.884	.243	.622	.527	.468
		recreational	**.021**	.884			.088	.767	.447	.504
		abuse	.243	.622	.088	.767			.019	.891
		dependence	.527	.468	.447	.504	**.019**	.891		

B

Pairwise Comparisons

			none		recreational		abuse		dependence	
	CHT STRATA	CA BEFORE PSY	Chi-Square	Sig.	Chi-Square	Sig.	Chi-Square	Sig.	Chi-Square	Sig.
Log Rank (Mantel-Cox)	low	none			64.541	<.001	90.310	<.001	152.073	<.001
		recreational	64.541	<.001			14.380	<.001	29.859	<.001
		abuse	90.310	<.001	14.380	<.001			.354	.552
		dependence	152.073	<.001	29.859	<.001	.354	.552		
	moderate	none			8.959	.003	7.932	.005	16.745	<.001
		recreational	8.959	.003			1.979	.160	5.064	.024
		abuse	7.932	.005	1.979	.160			.005	.946
		dependence	16.745	<.001	5.064	.024	.005	.946		
	medium	none			1.634	.201	.015	.903	.320	.572
		recreational	1.634	.201			1.462	.227	.120	.729
		abuse	.015	.903	1.462	.227			1.176	.278
		dependence	.320	.572	.120	.729	1.176	.278		
	high	none			6.532	.011	1.523	.217	.917	.338
		recreational	6.532	.011			.052	.819	.828	.363
		abuse	1.523	.217	.052	.819			.178	.673
		dependence	.917	.338	.828	.363	.178	.673		

Genotypes

Genotypes pre-imputation QC included missingness by marker <5%, missingness by sample <2%, minor allele frequency >1%, Inbreeding Coefficient (−0.2 > F_Het > 0.2), exclusion of monomorphic markers, Sex Check using X-chromosome heterozygosity and Y-chromosome call rate (all samples with sex mismatch were dropped). Detection of cryptic relatedness 2nd degree or closer was done with KING (5). Imputation to 1000 Genomes Phase3 V5 panel (www.internationalgenome.org) was performed at the Michigan Imputation Server using programs Minimac4 (3) for imputation and Eagle (4) for phasing. Post-imputation QC included missingness by individual 5%, missingness by marker 1%, HWE P<1E-05, and MAF 1%. The final imputed dataset contained 10,321,126 SNP markers.

Symptomatology Analyses

AO was significantly and inversely correlated with positive symptoms (r=-0.2, p=4.5 e-8), where to earlier AO corresponded a higher positive symptom score. A similar correlation was not found with negative symptomatology (r=-0.033, p>0.5). Positive symptomatology was positively correlated with total CHT score, where to higher trauma corresponds higher positive symptoms (r=0.197, p=2.6385E-10). This same relationship was not found between CHT and negative symptoms (r=0.06, p>0.05). By looking at CA users before or after AO, in CA users after AO, CHT positively correlated only with positive symptoms (r=0.16, p=0.002), while in CA users before AO, CHT correlated with both positive and negative symptoms. Both total PANSS positive and PANSS negative were inversely correlated with the BACS composite score (r=-0.12, p=0.0004; and r=-0.25, p=3.8015E-15), where to higher BACS composite score corresponded lower symptomatology. When looking at PRO with CA before or after AO, the significant relationship between BACS and positive and negative symptomatology was maintained in CA users before AO, while for CA users after AO, there was a significant inverse relationship with negative symptoms (r=0.149, p=0.003).

References

1. Aas M, Navari S, Gibbs A, et al. Is there a link between childhood trauma, cognition, and amygdala and hippocampus volume in first-episode psychosis? *Schizophr Res.* 2012;137(1-3):73-79.
2. Anda RF, Whitfield CL, Felitti VJ, et al. Adverse childhood experiences, alcoholic parents, and later risk of alcoholism and depression. *Psychiatr Serv.* 2002;53(8):1001-1009.
3. Anticevic A, Cole MW, Repovs G, et al. Characterizing thalamo-cortical disturbances in schizophrenia and bipolar illness. *Cereb Cortex.* 2014;24(12):3116-3130.
4. Arseneault L, Cannon M, Witton J, Murray RM. Causal association between cannabis and psychosis: examination of the evidence. *Br J Psychiatry.* 2004;184:110-117.
5. Baker JT, Holmes AJ, Masters GA, et al. Disruption of cortical association networks in schizophrenia and psychotic bipolar disorder. *JAMA Psychiatry.* 2014;71(2):109-118.
6. Beards S, Fisher HL, Gayer-Anderson C, et al. Threatening Life Events and Difficulties and Psychotic Disorder. *Schizophr Bull.* 2020;46(4):814-822.
7. Begemann MJH, Sommer IE, Brand RM, et al. Auditory verbal hallucinations and childhood trauma subtypes across the psychosis continuum: a cluster analysis. *Cogn Neuropsychiatry.* 2022;27(2-3):150-168.
8. Bernstein DP, Fink L, Handelsman L, et al. Initial reliability and validity of a new retrospective measure of child abuse and neglect. *Am J Psychiatry.* 1994;151(8):1132-1136.
9. Bremner JD, Krystal JH, Southwick SM, Charney DS. Functional neuroanatomical correlates of the effects of stress on memory. *J Trauma Stress.* 1995;8(4):527-553.
10. Carlyle M, Constable T, Walter ZC, Wilson J, Newland G, Hides L. Cannabis-induced dysphoria/paranoia mediates the link between childhood trauma and psychotic-like experiences in young cannabis users. *Schizophr Res.* 2021;238:178-184.
11. Choi SW, Mak TS, O'Reilly PF. Tutorial: a guide to performing polygenic risk score analyses. *Nat Protoc.* 2020;15(9):2759-2772.
12. Church C, Andreassen OA, Lorentzen S, Melle I, Aas M. Childhood Trauma and Minimization/Denial in People with and without a Severe Mental Disorder. *Front Psychol.* 2017;8:1276.
13. Cole JH, Franke K. Predicting Age Using Neuroimaging: Innovative Brain Ageing Biomarkers. *Trends Neurosci.* 2017;40(12):681-690.
14. Cougnard A, Goumilloux R, Monello F, Verdoux H. Time between schizophrenia onset and first request for disability status in France and associated patient characteristics. *Psychiatr Serv.* 2007;58(11):1427-1432.
15. Croft J, Heron J, Teufel C, et al. Association of Trauma Type, Age of Exposure, and Frequency in Childhood and Adolescence With Psychotic Experiences in Early Adulthood. *JAMA Psychiatry.* 2019;76(1):79-86.
16. Cross-Disorder Group of the Psychiatric Genomics C, Lee SH, Ripke S, et al. Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. *Nat Genet.* 2013;45(9):984-994.
17. Cross-Disorder Group of the Psychiatric Genomics Consortium. Electronic address pmhe, Cross-Disorder Group of the Psychiatric Genomics C. Genomic Relationships, Novel Loci, and Pleiotropic Mechanisms across Eight Psychiatric Disorders. *Cell.* 2019;179(7):1469-1482 e1411.
18. D'Souza DC, DiForti M, Ganesh S, et al. Consensus paper of the WFSBP task force on cannabis, cannabinoids and psychosis. *World J Biol Psychiatry.* 2022:1-24.

19. Danese A, Widom CS. The Subjective Experience of Childhood Maltreatment in Psychopathology. *JAMA Psychiatry.* 2021;78(12):1307-1308.
20. De la Pena-Arteaga V, Nogueira SO, Lynskey M, Hines LA. The Relationship Between Childhood Physical and Sexual Abuse and Adolescent Cannabis Use: A Systematic Review. *Front Psychiatry.* 2021;12:631245.
21. del Re EC ZV, Alliey-Rodriguez N, Lizano P, Bolo N, Lutz O, Pearson G, Sweeney JA, Clementz BA, Gershon E, Tamminga CA, Keshavan MS. Anterior-posterior axis of hippocampal subfields across psychoses: A B-SNIP study. *Biomarkers in Neuropsychiatry.* 2021;5:100037.
22. Di Forti M, Morgan C, Dazzan P, et al. High-potency cannabis and the risk of psychosis. *Br J Psychiatry.* 2009;195(6):488-491.
23. Di Forti M, Quattrone D, Freeman TP, et al. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. *Lancet Psychiatry.* 2019;6(5):427-436.
24. Di Forti M, Sallis H, Allegri F, et al. Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. *Schizophr Bull.* 2014;40(6):1509-1517.
25. Domen P, Michielse S, Peeters S, et al. Childhood trauma- and cannabis-associated microstructural white matter changes in patients with psychotic disorder: a longitudinal family-based diffusion imaging study. *Psychol Med.* 2019;49(4):628-638.
26. Drew WG, Miller LL. Cannabis: neural mechanisms and behavior--a theoretical review. *Pharmacology.* 1974;11(1):12-32.
27. Egertova M, Simon GM, Cravatt BF, Elphick MR. Localization of N-acyl phosphatidylethanolamine phospholipase D (NAPE-PLD) expression in mouse brain: A new perspective on N-acylethanolamines as neural signaling molecules. *J Comp Neurol.* 2008;506(4):604-615.
28. Essman EJ. Marijuana intoxication in rats: interruption of recent memory and effect on brain concentration of delta 9-tetrahydrocannabinol. *Psychol Rep.* 1984;55(2):563-567.
29. Gage SH, Hickman M, Zammit S. Association Between Cannabis and Psychosis: Epidemiologic Evidence. *Biol Psychiatry.* 2016;79(7):549-556.
30. Grillault Laroche D, Godin O, Belzeaux R, et al. Association between childhood maltreatment and the clinical course of bipolar disorders: A survival analysis of mood recurrences. *Acta Psychiatr Scand.* 2022;145(4):373-383.
31. Hajos M, Hoffmann WE, Kocsis B. Activation of cannabinoid-1 receptors disrupts sensory gating and neuronal oscillation: relevance to schizophrenia. *Biol Psychiatry.* 2008;63(11):1075-1083.
32. Hampson RE, Deadwyler SA. Role of cannabinoid receptors in memory storage. *Neurobiol Dis.* 1998;5(6 Pt B):474-482.
33. Hanna RC, Shalvoy A, Cullum CM, et al. Cognitive Function in Individuals With Psychosis: Moderation by Adolescent Cannabis Use. *Schizophr Bull.* 2016;42(6):1496-1503.
34. Harley M, Kelleher I, Clarke M, et al. Cannabis use and childhood trauma interact additively to increase the risk of psychotic symptoms in adolescence. *Psychol Med.* 2010;40(10):1627-1634.
35. Herkenham M, Lynn AB, Little MD, et al. Cannabinoid receptor localization in brain. *Proc Natl Acad Sci U S A.* 1990;87(5):1932-1936.
36. Iglesias JE, Augustinack JC, Nguyen K, et al. A computational atlas of the hippocampal formation using ex vivo, ultra-high resolution MRI: Application to adaptive segmentation of in vivo MRI. *Neuroimage.* 2015;115:117-137.
37. Ivleva EI, Bidesi AS, Keshavan MS, et al. Gray matter volume as an intermediate phenotype for psychosis: Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP). *Am J Psychiatry.* 2013;170(11):1285-1296.
38. Keefe RS, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L. The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. *Schizophr Res.* 2004;68(2-3):283-297.

39. Kendler KS, Bulik CM, Silberg J, Hettema JM, Myers J, Prescott CA. Childhood sexual abuse and adult psychiatric and substance use disorders in women: an epidemiological and cotwin control analysis. *Arch Gen Psychiatry.* 2000;57(10):953-959.
40. Keshavan MS, Paus T. Neurodevelopmental Trajectories, Disconnection, and Schizophrenia Risk. *JAMA Psychiatry.* 2015;72(9):943-945.
41. Keshavan MS. Development, disease and degeneration in schizophrenia: a unitary pathophysiological model. J Psychiatr Res. 1999 Nov-Dec;33(6):513-21.
41. Kline ER, Ferrara M, Li F, D'Souza DC, Keshavan M, Srihari VH. Timing of cannabis exposure relative to prodrome and psychosis onset in a community-based first episode psychosis sample. *J Psychiatr Res.* 2022;147:248-253.
42. Large M, Sharma S, Compton MT, Slade T, Nielssen O. Cannabis use and earlier onset of psychosis: a systematic meta-analysis. *Arch Gen Psychiatry.* 2011;68(6):555-561.
43. Legge SE, Jones HJ, Kendall KM, et al. Association of Genetic Liability to Psychotic Experiences With Neuropsychotic Disorders and Traits. *JAMA Psychiatry.* 2019;76(12):1256-1265.
44. Li L, Denholm R, Power C. Child maltreatment and household dysfunction: associations with pubertal development in a British birth cohort. *Int J Epidemiol.* 2014;43(4):1163-1173.
45. Liebschutz JM, Buchanan-Howland K, Chen CA, et al. Childhood Trauma Questionnaire (CTQ) correlations with prospective violence assessment in a longitudinal cohort. *Psychol Assess.* 2018;30(6):841-845.
46. Lo HF, Hong M, Szutorisz H, Hurd YL, Krauss RS. Delta9-Tetrahydrocannabinol inhibits Hedgehog-dependent patterning during development. *Development.* 2021;148(19).
47. Lutz PE, Turecki G. DNA methylation and childhood maltreatment: from animal models to human studies. *Neuroscience.* 2014;264:142-156.
48. Martinez-Mota L, Jimenez-Rubio G, Hernandez-Hernandez OT, Paez-Martinez N. Influence of the type of childhood violence on cannabis abuse and dependence among adolescents: a systematic review and meta-analysis. *Adicciones.* 2020;32(1):63-76.
49. McDonald SE, Shin S, Corona R, et al. Children exposed to intimate partner violence: Identifying differential effects of family environment on children's trauma and psychopathology symptoms through regression mixture models. *Child Abuse Negl.* 2016;58:1-11.
50. McGrath JJ, Saha S, Al-Hamzawi A, et al. Psychotic Experiences in the General Population: A Cross-National Analysis Based on 31,261 Respondents From 18 Countries. *JAMA Psychiatry.* 2015;72(7):697-705.
51. McGrath JJ, Saha S, Lim CCW, et al. Trauma and psychotic experiences: transnational data from the World Mental Health Survey. *Br J Psychiatry.* 2017;211(6):373-380.
52. McHugo M, Talati P, Woodward ND, Armstrong K, Blackford JU, Heckers S. Regionally specific volume deficits along the hippocampal long axis in early and chronic psychosis. *Neuroimage Clin.* 2018;20:1106-1114.
53. Meier MH, Beardslee J, Pardini D. Associations between Recent and Cumulative Cannabis Use and Internalizing Problems in Boys from Adolescence to Young Adulthood. *J Abnorm Child Psychol.* 2020;48(6):771-782.
54. Mesholam-Gately RI, Giuliano AJ, Goff KP, Faraone SV, Seidman LJ. Neurocognition in first-episode schizophrenia: a meta-analytic review. *Neuropsychology.* 2009;23(3):315-336.
55. Miller LL, Branconnier RJ. Cannabis: effects on memory and the cholinergic limbic system. *Psychol Bull.* 1983;93(3):441-456.
56. Mondelli V, Dazzan P. Childhood trauma and psychosis: Moving the field forward. *Schizophr Res.* 2019;205:1-3.
57. Morgan C, Gayer-Anderson C. Childhood adversities and psychosis: evidence, challenges, implications. *World Psychiatry.* 2016;15(2):93-102.

58. Murray RM, Englund A, Abi-Dargham A, et al. Cannabis-associated psychosis: Neural substrate and clinical impact. *Neuropharmacology.* 2017;124:89-104.
59. Nemeroff CB. Neurobiological consequences of childhood trauma. *J Clin Psychiatry.* 2004;65 Suppl 1:18-28.
60. Peeters SC, van de Ven V, Gronenschild EH, et al. Default mode network connectivity as a function of familial and environmental risk for psychotic disorder. *PLoS One.* 2015;10(3):e0120030.
61. Peters KZ, Zlebnik NE, Cheer JF. Cannabis exposure during adolescence: A uniquely sensitive period for neurobiological effects. *Int Rev Neurobiol.* 2022;161:95-120.
62. Pries LK, Guloksuz S, Ten Have M, et al. Evidence That Environmental and Familial Risks for Psychosis Additively Impact a Multidimensional Subthreshold Psychosis Syndrome. *Schizophr Bull.* 2018;44(4):710-719.
63. Read J, van Os J, Morrison AP, Ross CA. Childhood trauma, psychosis and schizophrenia: a literature review with theoretical and clinical implications. *Acta Psychiatr Scand.* 2005;112(5):330-350.
64. Schafer I, Fisher HL. Childhood trauma and psychosis - what is the evidence? *Dialogues Clin Neurosci.* 2011;13(3):360-365.
65. Seidman LJ, Buka SL, Goldstein JM, Tsuang MT. Intellectual decline in schizophrenia: evidence from a prospective birth cohort 28 year follow-up study. *J Clin Exp Neuropsychol.* 2006;28(2):225-242.
66. Sheffield JM, Kandala S, Tamminga CA, et al. Transdiagnostic Associations Between Functional Brain Network Integrity and Cognition. *JAMA Psychiatry.* 2017;74(6):605-613.
67. Shevlin M, Dorahy MJ, Adamson G. Trauma and psychosis: an analysis of the National Comorbidity Survey. *Am J Psychiatry.* 2007;164(1):166-169.
68. Spear LP. Adolescent brain development and animal models. *Ann N Y Acad Sci.* 2004;1021:23-26.
69. Teicher MH, Anderson CM, Ohashi K, et al. Differential effects of childhood neglect and abuse during sensitive exposure periods on male and female hippocampus. *Neuroimage.* 2018;169:443-452.
70. Teicher MH, Anderson CM, Polcari A. Childhood maltreatment is associated with reduced volume in the hippocampal subfields CA3, dentate gyrus, and subiculum. *Proc Natl Acad Sci U S A.* 2012;109(9):E563-572.
71. Teicher MH, Samson JA, Anderson CM, Ohashi K. The effects of childhood maltreatment on brain structure, function and connectivity. *Nat Rev Neurosci.* 2016;17(10):652-666.
72. Thermenos HW, Whitfield-Gabrieli S, Seidman LJ, et al. Altered language network activity in young people at familial high-risk for schizophrenia. *Schizophr Res.* 2013;151(1-3):229-237.
73. Trotta A, Iyegbe C, Di Forti M, et al. Interplay between Schizophrenia Polygenic Risk Score and Childhood Adversity in First-Presentation Psychotic Disorder: A Pilot Study. *PLoS One.* 2016;11(9):e0163319.
74. Yucel M, Lorenzetti V, Suo C, et al. Hippocampal harms, protection and recovery following regular cannabis use. *Transl Psychiatry.* 2016;6:e710.
75. Zanarini MC. Childhood experiences associated with the development of borderline personality disorder. *Psychiatr Clin North Am.* 2000;23(1):89-101.
76. Zlebnik NE, Cheer JF. Drug-Induced Alterations of Endocannabinoid-Mediated Plasticity in Brain Reward Regions. *J Neurosci.* 2016;36(40):10230-10238.